Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
RASopathies, a family of disorders characterized by cardiac defects, defective growth, facial dysmorphism, variable cognitive deficits and predisposition to certain malignancies, are caused by constitutional dysregulation of RAS signalling predominantly through the RAF/MEK/ERK (MAPK) cascade. We report on two germline mutations (p.Gly39dup and p.Val55Met) in RRAS, a gene encoding a small monomeric GTPase controlling cell adhesion, spreading and migration, underlying a rare (2 subjects among 504 individuals analysed) and variable phenotype with features partially overlapping Noonan syndrome, the most common RASopathy. We also identified somatic RRAS mutations (p.Gly39dup and p.Gln87Leu) in 2 of 110 cases of non-syndromic juvenile myelomonocytic leukaemia, a childhood myeloproliferative/myelodysplastic disease caused by upregulated RAS signalling, defining an atypical form of this haematological disorder rapidly progressing to acute myeloid leukaemia. Two of the three identified mutations affected known oncogenic hotspots of RAS genes and conferred variably enhanced RRAS function and stimulus-dependent MAPK activation. Expression of an RRAS mutant homolog in Caenorhabditis elegans enhanced RAS signalling and engendered protruding vulva, a phenotype previously linked to the RASopathy-causing SHOC2(S2G) mutant. Overall, these findings provide evidence of a functional link between RRAS and MAPK signalling and reveal an unpredicted role of enhanced RRAS function in human disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Self-citationThe cardiofaciocutaneous syndrome
Roberts, A., Allanson, J., Jadico, S. K., Kavamura, M. I., Noonan, J., Opitz, J. M., Young, T., & Neri, G. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.042796 · Cited by 271
Self-citationMarte, B. M., Rodriguez-Viciana, P., Wennström, S., Warne, P. H., & Downward, J. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00028-5 · Cited by 223 · cited 1×
“While PI3K/AKT has been recognized as a major effector pathway of RRAS, only a minor impact on MAPK signalling had been reported (41,42).”
BackgroundGremer, L., Merbitz-Zahradnik, T., Dvorsky, R., Cirstea, I. C., Kratz, C. P., Zenker, M., Wittinghofer, A., & Ahmadian, M. R. (2011) · Human Mutation · doi:10.1002/humu.21377 · Cited by 158
Self-citation
Cited by
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Ratner, N., & Miller, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3911 · Cited by 493
Recent advances in RASopathies
Aoki, Y., Niihori, T., Inoue, S.-I., & Matsubara, Y. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2015.114 · Cited by 373
Self-citationThe genomic landscape of juvenile myelomonocytic leukemia
Stieglitz, E., Taylor-Weiner, A. N., Chang, T. Y., Gelston, L. C., Wang, Y.-D., Mazor, T., Esquivel, E., Yu, A., Seepo, S., Olsen, S. R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3400 · Cited by 301
Self-citationCaye, A., Strullu, M., Guidez, F., Cassinat, B., Gazal, S., Fenneteau, O., Lainey, E., Nouri, K., Nakhaei-Rad, S., Dvorsky, R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3420 · Cited by 189
Self-citationFunctional dysregulation of CDC42 causes diverse developmental phenotypes
Martinelli, S., Krumbach, O. H. F., Pantaleoni, F., Coppola, S., Amin, E., Pannone, L., Nouri, K., Farina, L., Dvorsky, R., Lepri, F., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.12.015 · Cited by 188
Self-citationK-Ras V14I recapitulates Noonan syndrome in mice
Hernández-Porras, I., Fabbiano, S., Schuhmacher, A. J., Aicher, A., Cañamero, M., Cámara, J. A., Cussó, L., Desco, M., Heeschen, C., Mulero, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418126111 · Cited by 96
K‐RasV14I‐induced Noonan syndrome predisposes to tumour development in mice
Hernández‐Porras, I., Schuhmacher, A. J., Garcia‐Medina, R., Jiménez, B., Cañamero, M., de Martino, A., & Guerra, C. (2016) · The Journal of Pathology · doi:10.1002/path.4719 · Cited by 16
Metadata
- Authors
- Flex, E., Jaiswal, M., Pantaleoni, F., Martinelli, S., Strullu, M., Fansa, E. K., Caye, A., De Luca, A., Lepri, F., Dvorsky, R., Pannone, L., Paolacci, S., Zhang, S.-C., Fodale, V., Bocchinfuso, G., Rossi, C., Burkitt-Wright, E. M. M., Farrotti, A., Stellacci, E., Cecchetti, S., Ferese, R., Bottero, L., Castro, S., Fenneteau, O., Brethon, B., Sanchez, M., Roberts, A. E., Yntema, H. G., Van Der Burgt, I., Cianci, P., Bondeson, M.-L., Cristina Digilio, M., Zampino, G., Kerr, B., Aoki, Y., Loh, M. L., Palleschi, A., Di Schiavi, E., Care, A., Selicorni, A., Dallapiccola, B., Cirstea, I. C., Stella, L., Zenker, M., Gelb, B. D., Cave, H., Ahmadian, M. R., & Tartaglia, M.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-04-04
- Volume
- 23
- Issue
- 16
- Pages
- 4315-4327
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2156955613
- Cited by
- 144
- References
- 7
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.